Drug Database
NI

nitroglycerin (nitroglycerin, Alza / Nitroderm / Nitroderm TTS)

✓ Approved

Johnson & Johnson Services, Inc. · Small Molecule · Small Molecule

What is nitroglycerin?

nitroglycerin is a small molecule developed by Johnson & Johnson Services, Inc.. It is approved for therapeutic indications via topical or transdermal.

Drug Profile

Brand Namesnitroglycerin, Alza, Nitroderm, Nitroderm TTS
CompanyJohnson & Johnson Services, Inc.
Drug ClassSmall Molecule
RouteTopical, Transdermal
StatusApproved

Therapeutic Indications

nitroglycerin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Cardiac disordersAngina pectoris✓ Approved

Related Research Articles

PubMedCase reports in anesthesiology2026-08-25

Extreme Airway Difficulty During EXIT in Severe Fetal Agnathia: Failed Conventional Intubation and Successful Emergency Tracheostomy-A Case Report.

Muawad Rayan R, AlDhuwaihy Abdullah A, Alzomaia Hamad H, Kashgari Amna A et al.

Severe mandibular hypoplasia, particularly agnathia, is a rare congenital condition that may cause critical neonatal airway obstruction. The Ex Utero Intrapartum Treatment (EXIT) procedure allows airway control while maintaining uteroplacental circulation; overall airway establishment success rates for EXIT exceed 90%, yet conventional endotracheal intubation fails in a meaningful subset of cases with extreme anatomic distortion, necessitating surgical airway access. In the most severe forms of agnathia, primary tracheostomy under placental support may represent the most appropriate airway strategy from the outset. A 36-year-old gravida 5 para 4 woman was referred after prenatal ultrasound detected severe fetal facial abnormalities. Serial imaging demonstrated progressive micrognathia evolving toward agnathia. Prenatal ultrasound demonstrated a markedly abnormal inferior facial angle (IFA) of 11° (normal mean 65° ± 16°) and a fetal nasomental angle of 92.87° (normal approximately 147°), indicating profound mandibular hypoplasia. Fetal MRI performed at 35 weeks and 3 days confirmed these findings, demonstrating an IFA of 40° and a nasomental angle of 116°, both below normal thresholds. The pregnancy was complicated by severe polyhydramnios. Fetal magnetic resonance imaging confirmed near-complete absence of the mandible with glossoptosis and severe narrowing of the oropharynx and hypopharynx, while the distal trachea and bronchi appeared normal. Because of the anticipated risk of airway obstruction, a multidisciplinary team planned an EXIT-to-airway procedure at late preterm gestation. The mother underwent general anesthesia with rapid sequence induction using propofol and suxamethonium. Uterine relaxation was achieved via inhaled sevoflurane at 1.2 MAC and nitroglycerin infusion at 0.5 mcg/kg/min. Fetal heart rate was continuously monitored using a pulse oximeter applied to the fetal foot after partial delivery. During the procedure, attempts at airway establishment using video laryngoscopy and rigid bronchoscopy failed due to the inability to identify a recognizable epiglottis or glottic opening. The decision to proceed with emergency tracheostomy was made after three unsuccessful video laryngoscopy attempts, during which the airway appeared completely obliterated with no visible laryngeal inlet. Mask ventilation was also ineffective because of absent mandibular support and severe upper airway obstruction. An emergency tracheostomy was, therefore, performed while uteroplacental circulation was maintained, resulting in successful ventilation and stabilization of the neonate. This case highlights the limitations of conventional intubation during EXIT in fetuses with extreme mandibular deficiency. Detailed prenatal imaging is essential for anticipating airway challenges. In cases with complete upper airway obliteration, planned primary tracheostomy under placental support should be considered the primary airway strategy rather than a rescue measure.

PubMedJournal of cardiovascular computed tomography2026-08-22

Is nitroglycerin still necessary for coronary CT angiography in the era of photon-counting CT?

Kabakus Ismail M IM, Maisuria Dhruw M DM, Chamberlin Jordan H JH, Mencken Ian L IL et al.

Sublingual nitroglycerin is routinely administered before coronary computed tomography angiography (CCTA) to improve coronary artery visualization. However, most supporting evidence originates from older-generation CT systems and focuses on image quality rather than diagnostic accuracy. The impact of nitroglycerin on the diagnostic performance of photon-counting detector CT (PCD-CT) CCTA remains unknown. In this retrospective single-center study, consecutive patients who underwent photon-counting CCTA between January 2023 and November 2025 and invasive coronary angiography (ICA) within 30 days were identified. The final cohort consisted of 124 patients, including 61 who received sublingual nitroglycerin and 63 who did not. Diagnostic performance for detecting obstructive coronary artery disease was assessed on both a per-patient and per-vessel basis using ICA as the reference standard. Objective image quality was evaluated using coronary attenuation, signal-to-noise ratio (SNR), and contrast-to-noise ratio (CNR). On per-patient analysis, sensitivity was similar between the nitroglycerin and non-nitroglycerin cohorts (90.3% vs. 90.9%, p = 0.940), as was NPV (86.4% vs. 88.9%, p = 0.780). Non-nitroglycerin cohort demonstrated numerically higher specificity (80.0% vs. 63.3%, p = 0.160), PPV (83.3% vs. 71.8%, p = 0.250), and overall accuracy (85.7% vs. 77.0%, p = 0.220), although these differences were not statistically significant. No significant differences were observed on per-vessel analysis. Nitroglycerin increased coronary attenuation but did not improve SNR or CNR. In patients undergoing photon-counting CCTA, sublingual nitroglycerin administration was not associated with a statistically significant improvement in per-patient or per-vessel diagnostic performance. These findings should be considered hypothesis-generating and require confirmation in larger prospective studies before any conclusions can be drawn regarding the incremental value of routine nitroglycerin administration in photon-counting CCTA.

PubMedNeuroscience letters2026-08-22

Tuberomammillary histaminergic neurons are not required for behavioral responses in a Nitroglycerin-Induced acute headache mouse model.

Cao Ya Y, Yuan Huijian H, Na Weinan W, Yu Zhe Z et al.

The investigation into the association between histamine and headache has persisted for nearly a century. Nevertheless, the functional role of the central histaminergic system in headache pathophysiology remains inadequately characterized. This study aims to elucidate the activation status of tuberomammillary nucleus (TMN) histaminergic neurons in mice during acute headache episodes and their impact on headache-related behavioral alterations. Using transgenic mouse models, immunofluorescence staining, and chemogenetic manipulation, we systematically evaluated the functionality of histaminergic neurons in acute headache. c-Fos expression analysis and calcium signaling measurements were utilized to assess TMN neuronal activation. Our findings indicated that nitroglycerin (NTG) stimulation did not significantly alter the activation level of TMN histaminergic neurons, with no statistically significant differences observed between NTG-treated and control groups (p = 0.48, p = 0.92). Furthermore, calcium probe and histamine probe techniques revealed no substantial changes in neuronal activity during acute headache phases, suggesting a non-critical role for these neurons in acute headache responses. Anatomical tracing confirmed sparse projections from TMN histaminergic neurons to the trigeminal complex(TCC), reinforcing their limited involvement in pain signal transmission. Collectively, our results challenge the purported significance of central histaminergic neurons in acute headache pathophysiology within the NTG-induced mouse model and suggest that TMN histaminergic neurons do not show detectable activation and are not required for the behavioral endpoints tested in an NTG-induced acute headache mouse model.

PubMedJournal of cardiovascular computed tomography2026-08-21

Nitroglycerin-optimised coronary CT angiography in severe aortic stenosis: Shifting the burden of proof in pre-TAVR coronary assessment.

Giannopoulos Andreas A AA, Gaemperli Oliver O

PubMedJACC. Case reports2026-08-18

Eletriptan-Associated Coronary Vasospasm in a Heart Transplant Recipient.

Yong Yuanqi Y, Teng Lung En LE, Velusamy Ragani R, Layland Jamie J et al.

Triptans are serotonin 5-HT1B/5-HT1D receptor agonists used for migraine treatment that may precipitate coronary vasospasm in susceptible individuals, including heart transplant recipients. A 44-year-old woman with orthotopic heart transplantation and cardiac allograft vasculopathy developed acute chest pain shortly after first-dose eletriptan. Electrocardiography demonstrated inferior ST-segment elevation with troponin elevation. Coronary angiography showed severe dynamic narrowing of the right coronary artery with sluggish distal flow despite patent stents. Intracoronary nitroglycerin restored vessel caliber and distal flow, with resolution of chest pain and ST-segment elevation. This case demonstrates acute drug-induced coronary vasospasm following eletriptan use in a heart transplant recipient and highlights the importance of recognizing reversible vasospasm before escalating coronary intervention. Drug-induced coronary vasospasm should be considered in heart transplant recipients with acute coronary syndrome after exposure to vasoconstrictive medications. Recognition of reversible vasospasm may prevent unnecessary coronary intervention and inappropriate escalation of vasculopathy management.

PubMedJHLT open2026-08-10

Inhaled pulmonary vasodilators in pulmonary hypertension: Perioperative use and clinical considerations.

Klingbeil Rebecca R, Hjalmarsson Clara C, Colvin Bailey B, Kozarek Katherine K et al.

Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic condition associated with increased perioperative morbidity and mortality, particularly in patients undergoing cardiac or high-risk non-cardiac surgery. Inhaled pulmonary vasodilators (iPVs) offer a targeted strategy to reduce pulmonary vascular resistance (PVR) and improve right ventricular (RV) function while minimizing systemic hypotension. Traditional vasodilators such as nitroglycerin and sodium nitroprusside lack pulmonary specificity and can exacerbate systemic hypotension. Inhaled agents including nitric oxide (NO), epoprostenol (iEPO), iloprost, milrinone (iMIL) and levosimendan provide selective pulmonary vasodilation with more favorable hemodynamic profiles. This narrative review summarizes current evidence and clinical considerations for the use of iPVs in the perioperative management of PH and discusses pharmacokinetics, delivery mechanisms, adverse effects, and logistical considerations for these agents. New emerging PH therapies are included based on early clinical trial data as they have the potential to impact perioperative care in the future. Overall, iPVs represent a valuable tool in the perioperative care of patients with PH. Continued research is needed to refine clinical protocols, evaluate emerging agents, and establish outcome-based evidence for their routine use.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about nitroglycerin